NCT03036865View on ClinicalTrials.gov

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

April 27, 2018

Study Completion Date

April 27, 2018

Conditions
Healthy Participants
Interventions
DRUG

BOS161721

Single dose administered IV or SC

DRUG

Placebo

Single dose administered IV or SC

Trial Locations (1)

Unknown

Baltimore

Sponsors
All Listed Sponsors
lead

Boston Pharmaceuticals

INDUSTRY

NCT03036865 - Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects | Biotech Hunter | Biotech Hunter